How can overall survival even be considered an endpoint in studies like Verona if the study is being muddled by giving some other drug instead of placebo+aza. In this case, according to Juho, some doctors had replaced the placebo with Venetoclax.
I understand the ethical side, of course, and that’s exactly why the study design feels strange regarding the endpoint. CR or some other endpoint would make more sense.